Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 10/20 | 0.54 |
| ▸ | DRD2 | P14416 | 8/20 | 0.52 |
| ▸ | DRD3 | P35462 | 8/20 | 0.52 |
| ▸ | HTR1A | P08908 | 2/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2395932 | 0.87 | DRD4 (0.67) | DRD4DRD2DRD3HTR1AHDAC4 | |
| SCHEMBL7975118 | 0.86 | DRD4 (0.59) | DRD4DRD2DRD3HTR1AHDAC4 | |
| Hydrochloric Acid SCHEMBL8346217 | 0.85 | DRD4 (0.58) | DRD4DRD2DRD3HTR1AHDAC4 | |
| SCHEMBL6585625 | 0.84 | DRD4 (0.63) | DRD4DRD2DRD3HTR1AHDAC4 | |
| SCHEMBL29188191 | 0.84 | DRD4 (0.67) | DRD4DRD2DRD3HTR1AHDAC4 | |
| SCHEMBL6043125 | 0.84 | MEN1 (0.58) | DRD4DRD2DRD3HTR1AHDAC4 | |
| SCHEMBL6041687 | 0.84 | DRD4 (0.54) | DRD4DRD2DRD3HTR1AHDAC4 | |
| SCHEMBL4827185 | 0.81 | MEN1 (0.71) | DRD4DRD2DRD3HTR1APARP1 | |
| SCHEMBL4827187 | 0.81 | DRD4 (0.54) | DRD4DRD2DRD3HTR1AHDAC4 | |
| SCHEMBL2582694 | 0.80 | HDAC4 (0.58) | DRD4DRD2DRD3HTR1AHDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130225825-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-08-29 | — | — | US | claimed |
| JP-4851440-B2 | — | — | 2012-01-11 | — | — | JP | claimed |
| CN-101429194-B | Process for the preparation of tryptase inhibitors | AVENTIS PHARMACEUTICALS, INC. (US) | 2011-12-14 | — | — | CN | claimed |
| EP-1723140-B1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | AVENTIS PHARMA INC (US) | 2009-11-04 | — | — | EP | claimed |
| CN-101429194-A | Process for the preparation of tryptase inhibitors | AVENTIS PHARMA INC (US) | 2009-05-13 | — | — | CN | claimed |
| US-20070197597-A1 | Process for the preparation of tryptase inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-23 | — | — | US | claimed |
| CN-1950362-A | Preparation method of tryptase inhibitor | AVENTIS PHARMA INC (US) | 2007-04-18 | — | — | CN | claimed |
| EP-1723140-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2006-11-22 | — | — | EP | claimed |
| WO-2005095385-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-13 | — | — | WO | claimed |
| EP-1571150-A1 | Process for the preparation of tryptase inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2005-09-07 | — | — | EP | claimed |
| US-20130225825-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2013-08-29 | — | — | US | disclosed |
| CN-101429194-B | Process for the preparation of tryptase inhibitors | AVENTIS PHARMACEUTICALS, INC. (US) | 2011-12-14 | — | — | CN | disclosed |
| US-20110015400-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-01-20 | — | — | US | disclosed |
| US-20110015400-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-01-20 | — | — | US | disclosed |
| CN-1950362-B | Preparation method of tryptase inhibitor | AVENTIS PHARMA INC | 2010-08-04 | — | — | CN | disclosed |
| US-20070197597-A1 | Process for the preparation of tryptase inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
| CN-1950362-A | Preparation method of tryptase inhibitor | AVENTIS PHARMA INC (US) | 2007-04-18 | — | — | CN | disclosed |
| EP-1723140-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005095385-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| EP-1571150-A1 | Process for the preparation of tryptase inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2005-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225825-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | CMA1, TPSAB1, TPSB2 | DRD4 3249/4885DRD2 3103/4885DRD3 2874/4885 |
| US-20110015400-A1 | PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS | CMA1, TPSAB1, TPSB2 | DRD4 3249/4885DRD2 3103/4885DRD3 2874/4885 |
| US-20070197597-A1 | Process for the preparation of tryptase inhibitors | CMA1, TPSAB1, TPSB2 | DRD4 3249/4885DRD2 3103/4885DRD3 2874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.